TLX101-Tx is Telix's investigational LAT1-targeted therapeutic candidate in clinical development for recurrent or progressive glioblastoma. It is being studied in an ongoing multicenter Phase 2 trial and remains unapproved. The program is linked mechanistically with LAT1-targeted imaging strategies in the same portfolio.
Telix Pharmaceuticals has submitted regulatory applications for TLX101-Px, a brain cancer imaging agent, to both the European Medicines Agency and the U.S. Food and Drug Administration, seeking approval for glioma diagnosis and treatment monitoring.
Telix Pharmaceuticals submitted a marketing authorization application in Europe for TLX101-Px, a glioma imaging agent, on February 18, 2026. The filing covers major European markets and a U.S. NDA submission will follow.
